ENGENE HOLDINGS INC (ENGN) Stock Price, Forecast & Analysis
NASDAQ:ENGN • CA29286M1059
ENGN Key Statistics, Chart & Performance
The current stock price of ENGN is 9.9425 USD. In the past month the price decreased by -14.21%. In the past year, price increased by 62.73%.
ENGN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ENGN. When comparing the yearly performance of all stocks, ENGN is one of the better performing stocks in the market, outperforming 89.67% of all stocks.
ENGN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ENGN. ENGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ENGN Financial Highlights
Over the last trailing twelve months ENGN reported a non-GAAP Earnings per Share(EPS) of -2.29. The EPS decreased by -52.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.97% | ||
| ROE | -69.94% | ||
| Debt/Equity | 0.09 |
ENGN Forecast & Estimates
18 analysts have analysed ENGN and the average price target is 24.48 USD. This implies a price increase of 146.22% is expected in the next year compared to the current price of 9.9425.
ENGN Ownership
ENGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.62 | 403.74B | ||
| AMGN | AMGEN INC | 17.01 | 206.168B | ||
| GILD | GILEAD SCIENCES INC | 16.53 | 183.174B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.65 | 123.671B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.86 | 81.636B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.88 | 43.973B | ||
| INSM | INSMED INC | N/A | 33.829B | ||
| NTRA | NATERA INC | N/A | 29.154B | ||
| BIIB | BIOGEN INC | 12.49 | 28.637B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.8 | 20.386B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ENGN
Company Profile
enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 45 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The firm is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Company Info
ENGENE HOLDINGS INC
4868 Rue Levy, Suite 220
Saint-Laurent QUEBEC CA
Employees: 45
Phone: 15143324888
ENGENE HOLDINGS INC / ENGN FAQ
What does ENGN do?
enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 45 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The firm is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
What is the stock price of ENGENE HOLDINGS INC today?
The current stock price of ENGN is 9.9425 USD. The price increased by 1.66% in the last trading session.
Does ENGENE HOLDINGS INC pay dividends?
ENGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of ENGN stock?
ENGN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy ENGN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ENGN.
What is the market capitalization of ENGN stock?
ENGENE HOLDINGS INC (ENGN) has a market capitalization of 665.95M USD. This makes ENGN a Small Cap stock.